Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SYN Stock Summary
In the News
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript
Synthetic Biologics, Inc. (NYSE:SYN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive & Chief Financial Officer Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Laura Suriel - Alliance Global Partners Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Synthetic Biologics' Second Quarter 2022 Earnings Call. Today's conference is being recorded.
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call Transcript
Synthetic Biologics, Inc. (NYSE:SYN ) Q1 2022 Earnings Conference Call May 16, 2022 9:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and CFO Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Jim Molloy - Alliance Global Partners Leland Gershell - Oppenheimer Operator Greetings, and welcome to Synthetic Biologics' First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.
Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update.
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript
Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results
ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Wednesday, March 16, 2022, at 4:30 p.m. ET to discuss its financial results for the year ended December 31, 2021 and provide a corporate update.
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference
ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the 2022 BIO CEO & Investor Conference being held February 14-17, 2022.
Synthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call Transcript
Synthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call Transcript
5 Top Penny Stocks To Buy For Under $5 On Webull Today
Are these penny stocks on your Webull watch list? The post 5 Top Penny Stocks To Buy For Under $5 On Webull Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021
ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2021 on Wednesday, November 3, 2021, and to host a conference call the same day at 4:30 p.m.
SYN Financial details
SYN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -21.45 | -9.31 | -5.28 | -1.17 | -1.28 | |
Operating cash flow per share | -27.72 | -8.44 | -6.4 | -1.06 | -1.24 | |
Free cash flow per share | -27.74 | -8.44 | -6.41 | -1.06 | -1.25 | |
Cash per share | 46.4 | 9.15 | 3.28 | 5.52 | 2.73 | |
Book value per share | 47.11 | 8.74 | 4.22 | 5.37 | 3.38 | |
Tangible book value per share | 42.45 | 6.99 | 2.77 | 5.37 | 3.2 | |
Share holders equity per share | 47.11 | 8.74 | 4.22 | 5.37 | 3.38 | |
Interest debt per share | 0 | 0.44 | 0.25 | 0.13 | 0.08 | |
Market cap | 349.02K | 833.25K | 728.14K | 3.32M | 15.63M | |
Enterprise value | -28.57M | -13.49M | -5.03M | -62.48M | -24.47M | |
P/E ratio | -0.03 | -0.05 | -0.07 | -0.23 | -0.79 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.02 | -0.06 | -0.06 | -0.26 | -0.82 | |
PFCF ratio | -0.02 | -0.06 | -0.06 | -0.26 | -0.81 | |
P/B Ratio | 0.01 | 0.06 | 0.09 | 0.05 | 0.3 | |
PTB ratio | 0.01 | 0.06 | 0.09 | 0.05 | 0.3 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 2.18 | 0.9 | 0.51 | 4.41 | 1.13 | |
EV to operating cash flow | 1.65 | 0.97 | 0.41 | 4.85 | 1.28 | |
EV to free cash flow | 1.65 | 0.97 | 0.41 | 4.84 | 1.27 | |
Earnings yield | -38.3 | -18.37 | -13.79 | -4.3 | -1.26 | |
Free cash flow yield | -49.53 | -16.65 | -16.72 | -3.89 | -1.23 | |
Debt to equity | 0 | 0.05 | 0.06 | 0.02 | 0.03 | |
Debt to assets | 0 | 0.04 | 0.06 | 0.02 | 0.02 | |
Net debt to EBITDA | 2.21 | 0.95 | 0.58 | 4.64 | 1.86 | |
Current ratio | 8.72 | 3.11 | 2.67 | 19.37 | 6.45 | |
Interest coverage | 0 | 0 | 0 | -2.38K | 45.82 | |
Income quality | 1.29 | 0.91 | 1.21 | 0.9 | 0.97 | |
Dividend Yield | 33.47 | 0.63 | 1.9 | 0.45 | 0 | |
Payout ratio | -0.87 | -0.03 | -0.14 | -0.1 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.08 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.03 | 0 | -0.04 | -0.16 | -1.36 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 150.78 | 42.78 | 22.41 | 11.89 | 9.89 | |
ROIC | -0.78 | -1.01 | -1.14 | -0.21 | -0.37 | |
Return on tangible assets | -0.44 | -0.89 | -1.19 | -0.2 | -0.3 | |
Graham Net | 40.48 | 5.66 | 1.8 | 5.12 | 1.6 | |
Working capital | 26.13M | 11.15M | 4.97M | 65.3M | 38.46M | |
Tangible asset value | 26.46M | 11.49M | 5.26M | 65.41M | 49.04M | |
Net current asset value | 25.83M | 10.68M | 4.78M | 63.9M | 28.22M | |
Invested capital | 0 | 0.05 | 0.06 | 0.02 | 0.03 | |
Average receivables | 23K | 1.5K | 236K | 234.5K | 0 | |
Average payables | 1.53M | 1.67M | 1.6M | 705K | 719.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.46 | -1.07 | -1.25 | -0.22 | -0.38 | |
Capex per share | -0.01 | 0 | 0 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.34 | -0.34 | -0.3 | -0.34 | -0.19 | |
Operating cash flow per share | 0 | -0.33 | -0.37 | 0 | 0 | |
Free cash flow per share | 0 | -0.33 | -0.37 | 0 | 0 | |
Cash per share | 3.24 | 2.73 | 2.39 | 2.26 | 1.83 | |
Book value per share | 3.56 | 3.38 | 3.16 | 2.97 | 2.41 | |
Tangible book value per share | 3.46 | 3.2 | 2.97 | 2.78 | 2.25 | |
Share holders equity per share | 3.56 | 3.38 | 3.16 | 2.97 | 2.41 | |
Interest debt per share | 0.12 | 0.11 | 0.14 | 0.16 | 0.12 | |
Market cap | 15.37M | 15.63M | 15.43M | 15.47M | 17.38M | |
Enterprise value | -33.47M | -24.47M | -18.18M | -16.42M | -11.7M | |
P/E ratio | -0.72 | -0.76 | -0.86 | -0.76 | -1.32 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | -3.12 | -2.75 | 0 | 0 | |
PFCF ratio | 0 | -3.06 | -2.75 | 0 | 0 | |
P/B Ratio | 0.28 | 0.3 | 0.32 | 0.34 | 0.42 | |
PTB ratio | 0.28 | 0.3 | 0.32 | 0.34 | 0.42 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 6.67 | 3.66 | 3.51 | 2.82 | 2.77 | |
EV to operating cash flow | 0 | 4.88 | 3.24 | 0 | 0 | |
EV to free cash flow | 0 | 4.78 | 3.24 | 0 | 0 | |
Earnings yield | -0.35 | -0.33 | -0.29 | -0.33 | -0.19 | |
Free cash flow yield | 0 | -0.33 | -0.36 | 0 | 0 | |
Debt to equity | 0.03 | 0.03 | 0.05 | 0.05 | 0.05 | |
Debt to assets | 0.02 | 0.02 | 0.04 | 0.04 | 0.03 | |
Net debt to EBITDA | 9.74 | 6 | 6.49 | 5.48 | 6.9 | |
Current ratio | 4 | 6.45 | 4.68 | 4.16 | 3.98 | |
Interest coverage | -28.01 | 221.2 | 13.99 | 0 | 0 | |
Income quality | 0 | 0.97 | 1.25 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.05 | 0.08 | 0.08 | 0.09 | 0.09 | |
Capex to operating cash flow | 0 | 0.02 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -2.83 | -0.25 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.25 | 5.06 | 4.59 | 4.73 | 3.24 | |
ROIC | -0.09 | -0.09 | -0.09 | -0.12 | -0.08 | |
Return on tangible assets | -0.07 | -0.08 | -0.07 | -0.08 | -0.06 | |
Graham Net | 1.92 | 1.6 | 1.24 | 1.09 | 0.79 | |
Working capital | 39.54M | 38.46M | 31.68M | 28.83M | 26.02M | |
Tangible asset value | 53.9M | 49.04M | 44.97M | 42.13M | 38.42M | |
Net current asset value | 32.19M | 28.22M | 23M | 20.27M | 17.11M | |
Invested capital | 0.03 | 0.03 | 0.05 | 0.05 | 0.05 | |
Average receivables | 139K | 0 | 0 | 0 | 0 | |
Average payables | 886.5K | 842.5K | 697.5K | 610.5K | 787K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.1 | -0.1 | -0.09 | -0.11 | -0.08 | |
Capex per share | 0 | -0.01 | 0 | 0 | 0 |
SYN Frequently Asked Questions
What is Synthetic Biologics, Inc. stock symbol ?
Synthetic Biologics, Inc. is a US stock , located in Rockville of Maryland and trading under the symbol SYN
What is Synthetic Biologics, Inc. stock quote today ?
Synthetic Biologics, Inc. stock price is $1.02 today.
Is Synthetic Biologics, Inc. stock public?
Yes, Synthetic Biologics, Inc. is a publicly traded company.